在BRAF中发生突变特异性的结构变化:了解针对性治疗的二分化和药物结合
Minjie Zhao1,2, Rabia Zafar3, Saad Serfraz3
1Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
致癌的BRAF突变通过改变蛋白质结构和药物相互作用来破坏癌症信号传递. 了解这些结构变化指导精密瘤疗法,以更好地治疗癌症.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- BRAF突变是各种癌症的关键驱动因素,影响MAPK/ERK通路.
- 了解BRAF突变的结构和生物物理影响对于向治疗至关重要.
研究的目的:
- 研究五种BRAF突变 (V600E,G469E,D594G,N581S,E586K) 的结构和生物物理后果.
- 分析这些突变对二分化,ATP结合和与Sorafenib和U0126.6的药物相互作用的影响.
主要方法:
- 利用分子动力学模拟来分析蛋白质的结构变化.
- 进行了ATP结合评估和药物相互作用分析.
- 进行了自由能量和紧性分析,以了解构造性景观.
主要成果:
- V600E突变促进了一个稳定的单体活性形式,赋予索拉费尼布耐药性.
- G469E显示中间活性和药物反应性,保留了二分化依赖性.
- D594G是非激酶活性的,但会激活CRAF,具有有限的药物敏感性.
- 良性突变保持了与野生类型相似的结构和功能特性.
结论:
- 在BRAF中发生的突变特异性结构变化会影响激酶活性,二分化和药物反应.
- 这些发现提供了BRAF突变结构和功能之间的机制联系.
- 支持在精密瘤学中开发突变引导的治疗策略.
更多相关视频
06:44Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
Published on: March 1, 2024
10:16Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
Published on: October 8, 2015
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Abnormal Proliferation
